NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). 12.2…
Clinical Trials (5)
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Started Apr 2018
36 enrolled
Major Depressive Disorder
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Started Nov 2017
59 enrolled
Hot FlashesBreast Neoplasms
Desvenlafaxine in Opioid-Dependent Patients
Started Jul 2014
18 enrolled
DepressionOpioid DependenceMethadone Treatment
Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Started Feb 2012
59 enrolled
Dysthymic DisorderDysthymiaChronic Depressive Disorder
Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
Started Nov 2011
36 enrolled
Major Depressive Disorder